EW Weekly, March 29, 2019
- Top-line results announced from Phase 3 ALLEVIATE trial for allergic conjunctivitis
- Phase 2 trial of NCX 4251 for blepharitis begins
- Phase 2b study for CSF-1 to treat presbyopia begins
- Clinical trial for retinitis pigmentosa treatment advances
- Adhesive gel that can seal corneal cuts and ulcers could help repair injuries
- Alcon spin-off by Novartis planned for April
- ASCRS ASOA Annual Meeting Tier Two registration deadline April 3
- Register now: FDA and ophthalmic community workshop on laser-based imaging
Top-line results announced from Phase 3 ALLEVIATE trial for allergic conjunctivitis
Phase 2 trial of NCX 4251 for blepharitis begins
Phase 2b study for CSF-1 to treat presbyopia begins
Clinical trial for retinitis pigmentosa treatment advances
Adhesive gel that can seal corneal cuts and ulcers could help repair injuries
ASCRS ASOA Annual Meeting Tier Two registration deadline April 3
*Must have current membership to attend the Annual Meeting
**Does not include Skills Transfer Labs
Register now: FDA and ophthalmic community workshop on laser-based imaging
Research briefs
- In an assessment with 244 patients, Brian Pall, OD, and researchers demonstrated the efficacy of contact lens delivery of a therapeutic for ocular allergy. The contact lens contained the antihistamine ketotifen and was tested in two parallel, conjunctival allergen challenge-based trials. Both multicenter, randomized, placebo-controlled trials used etafilcon A test lenses with 0.019 mg ketotifen or etafilcon A control lenses with no ketotifen. The primary endpoint was ocular itching measured with a 0 to 4 scale with half-unit steps. Mean itching scores were lower for test lens eyes compared to controls. The mean differences in itching were clinically and statistically significant. The research is published in Cornea.
- Topography-guided custom treatment led to better achieved visual acuity than the preop corrected distance visual acuity (CDVA) in more than 25% of eyes in a retrospective case series, reported Vinicius De Stefano, MD, and coresearchers. Their research focused on planning strategies for eyes that gained one or more lines of CDVA after topography-guided custom treatment. Among the 256 eyes included in the study, all had topography-guided treatment by the same surgeon. The uncorrected distance visual acuity was 20/20 or better in 95.7% of eyes at 3 months and 20/15 or better in 81.4% of eyes. Nearly 26% of eyes gained one or more lines of CDVA. Tomography and wavefront aberrometry helped to select eyes that would achieve optimum visual outcomes. The study is published in the Journal of Cataract & Refractive Surgery.
- The A/B/S Ultrasound Platform ABSolu (Quantel Medical) has received approval from the U.S. FDA.
This issue of EyeWorld Weekly Update was edited by Amy Goldenberg and Vanessa Caceres.
EyeWorld Weekly Update (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrators, is published every Friday, distributed by email, and posted live on Friday.
Medical Editors: Eric Donnenfeld, MD, chief medical editor; Rosa Braga-Mele, MD, cataract editor; Clara Chan, MD, cornea editor; Nathan Radcliffe, MD, glaucoma editor; and Vance Thompson, MD, refractive editor.
For sponsorship opportunities or membership information, contact:
ASCRS•ASOA • 4000 Legato Rd. • Suite 700 • Fairfax, VA 22033 • Phone: 703-591-2220 • Fax: 703-591-0614 • Email: ASCRS
Opinions expressed in EyeWorld Weekly Update do not necessarily reflect those of ASCRS•ASOA. Mention of products or services does not constitute an endorsement by ASCRS•ASOA.
Click here to view our Legal Notice.